More than 50% of prostate cancer is low-risk. These survivor stories detail how genomic testing helped determine the treatment plan that was right for them.
Jim and his doctor used the Oncotype DX Genomic Prostate Score to determine that active surveillance was the best course of treatment for his prostate cancer.
Buddy and his doctor used genomic testing to form a treatment plan for his low-risk prostate cancer.
After multiple medical opinions, Greg turned to genomic testing to discover his prostate cancer was non-aggressive.
Are you a survivor, caregiver, or loved one of someone with prostate cancer?